- Home
- BTOG vs PRFX Comparison
BTOG vs PRFX Comparison
Compare BTOG & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTOG | PRFX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.6M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTOG | PRFX |
|---|---|---|
| Price | $2.03 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.3K | ★ 1.8M |
| Earning Date | 06-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.58 |
| 52 Week High | $5.96 | $5.39 |
Technical Indicators
Market Signals| Indicator | BTOG | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 41.99 |
| Support Level | $1.67 | $0.95 |
| Resistance Level | $2.29 | $1.54 |
| Average True Range (ATR) | 0.16 | 0.40 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 91.26 | 1.96 |
Price Performance
Historical ComparisonAbout BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.